Floatz logo

L-CYSTEINAMIDE, D-PHENYLALANYL-L-CYSTEINYL-L-PHENYLALANYL-D-TRYPTOPHYL-L-LYSYL-L-THREONYL-N-(2-HYDROXY-1-(HYDROXYMETHYL)PROPYL)-, CYCLIC (2->7)-DISULFIDE, (R-(R*,R*))-

Hepatorenal Syndrome

University of California, Los Angelesprotein_peptidePhase 2/3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the Hepatorenal Syndrome cohort.

Asset / SponsorPhaseRating
Gly-Gly-Gly-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-Nh2 (4-9 Disulfide)
Noorik Biopharmaceuticals AG
Phase 4A
NORMAL HUMAN SERUM ALBUMIN
Massachusetts General Hospital
Phase 4BBB
Norfloxacin
Hospital Clinic of Barcelona
Phase 4BB
Midodrine
University of California, Los Angeles
Phase 2/3BB
[Phe^2,Ile^3,Dab(PhAc-D-Tyr(Me)-Phe-Gln-Asn-Ala-Pro-Arg-iGln-Lys(Ac)-Epsilon-Lys)^8]vasopressin
Ocelot Bio, Inc
Phase 2B

View all 10 →

Same molecule, other indications

L-CYSTEINAMIDE, D-PHENYLALANYL-L-CYSTEINYL-L-PHENYLALANYL-D-TRYPTOPHYL-L-LYSYL-L-THREONYL-N-(2-HYDROXY-1-(HYDROXYMETHYL)PROPYL)-, CYCLIC (2->7)-DISULFIDE, (R-(R*,R*))- is also rated in:

esophageal varicesDormant
BB
Indicative · Phase 4
71 / 100
View asset →
diarrheal diseaseDormant
BB
Indicative · Phase 3
71 / 100
View asset →
cirrhosis of liverDormant
BB
Indicative · Phase 4
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →